← All indications
Irritable Bowel Syndrome
A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
Drugs by status
Approved for this indication (18)
Phase 4 trials (53)
- metronidazole
- propofol
- vitamin d3
- amitriptyline
- bacillus clausii
- bifidobacterium animalis
- paroxetine
- colesevelam
- pancrelipase
- duloxetine
- Ebastine
- vitis vinifera
- Fenoverine
- gabapentin
- escitalopram
- mesalamine
- simethicone
- ramosetron
- mebeverine
- nitazoxanide
- saccharomyces boulardii
- tiropramide
- pentoxifylline
- ondansetron
- bifidobacterium infantis
- bifidobacterium breve
- bifidobacterium longum
- curcumin
- clostridium butyricum
- ganedenbc30
- +23 more
Phase 3 trials (35)
- melatonin
- maltodextrin
- anise
- asimadoline
- dexloxiglumide
- ethosuximide
- secretin human
- Iberis amara
- ibodutant
- n-acetylglucosamine
- pectin
- lactose
- plecanatide
- prucalopride succinate
- pumosetrag
- ranolazine
- renzapride
- tong-xie-yao-fang
- verapamil
- xiang-sha-liu-jun-zi-tang
- brown seaweed
- autologous microbiome
- human fecal microbiota
- fructan
- lonicera japonica
- chickpea
- pyridoxine
- galactooligosaccharide
- peppermint extract
- psyllium
- +5 more
Phase 2 trials (65)
- lx1033
- aquamin
- acetylcysteine
- asp7147
- kremezin
- chang'an i
- citalopram
- crofelemer
- da jian zhong tang
- ddp225
- dextofisopam
- dnk333
- dt01
- palmitoylethanolamide
- l-glutamine
- emicerfont
- hypericum perforatum
- itropride
- lx1031
- dronabinol
- vibegron
- verucerfont
- ono-2952
- human milk
- pd-217,014
- pexacerfont
- rimegepant
- polydotin
- lidocaine
- rifamycin
- +35 more
Phase 1 trials (15)
Other trials (70)
- sucrose
- aloe vera
- atractylodes
- ayurvedic herbs
- capsaicin
- cannabidiol
- fiber
- fingered citron
- ginger
- esketamine
- ledebouriella root
- beta-glucans
- paeonia lactiflora
- cow milk
- piromelatine
- magnesium sulfate
- infloran
- radix codonopsitis
- radix curcumae
- shugan
- sodium butyrate
- tangerine peel
- bupivacaine
- shigyaku-san
- tuckahoe
- activia
- apple
- bifidobacteria adolescentis bd1
- caraway seed
- fructo-oligosaccharide
- +40 more
Organizations
Organization Involved with Phase 4 Indications (69)
- Ironwood Pharmaceuticals
- Astellas
- Eli Lilly
- Tillotts Pharma
- Sanofi
- Novartis
- Allergan
- Bukwang Pharmaceutical
- Danisco
- GlaxoSmithKline
- Laboratoires Mayoly Spindler
- Nabiqasim Industries (Pvt) Ltd
- Norgine
- Pileje
- SOFAR S.p.A.
- Daewoong Pharmaceutical Co. LTD.
- National Center for Research Resources (NCRR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Southampton
- Maastricht University
- American Academy of Family Physicians
- University of London
- China Academy of Chinese Medical Sciences
- Harvard University
- Dow University of Health Sciences
- Duke University
- Hospital Juarez de Mexico
- Katholieke Universiteit Leuven
- King Fahad Medical City
- Johns Hopkins University
- +39 more
Organization Involved with Phase 3 Indications (73)
- Alimentary Health Ltd
- Alizyme
- Axcan
- Takeda
- Shire
- Bausch Health Companies
- AstraZeneca
- AGI Therapeutics, Inc.
- Ardelyx
- Bayer
- Bio-K Plus International Inc.
- Biocodex
- Cell Biotech Co., Ltd.
- InQpharm Group
- Menarini Group
- Next Gen Pharma India Pvt. Ltd.
- Synergy Pharmaceuticals
- Tioga Pharmaceuticals
- ChiRhoClin, Inc.
- Dynogen Pharmaceuticals
- Rottapharm
- ZonMw: The Netherlands Organisation for Health Research and Development
- Huazhong University of Science and Technology
- Azad University
- Cairo University
- Flinders University
- Harbin Medical University
- Helse Møre og Romsdal HF
- Hospital Britanico
- Indian Council of Medical Research
- +43 more
Organization Involved with Phase 2 Indications (81)
- PPD
- Abbott
- DuPont
- Pharmos
- Targacept
- Bristol-Myers Squibb
- Cato Research
- Pfizer
- Arena Pharmaceuticals
- Atlantia Food Clinical Trials
- BioBalance Corporation
- Boston Pharmaceuticals
- CM&D Pharma
- Cosmo Pharmaceuticals
- Glycom A/S
- Lallemand SAS
- Lexicon Pharmaceuticals
- Nutrabiotix, LLC
- Ocera Therapeutics
- Probi AB
- Pharmabiotix Inc
- Revogenex, Inc.
- Tasly Pharmaceuticals, Inc.
- National Institutes of Health (NIH)
- Göteborg University
- Aarhus University
- Augusta University
- Cedars-Sinai Medical Center
- Cornell University
- McMaster University
- +51 more
Organization Involved with Phase 1 Indications (12)
- Avera Pharmaceuticals
- Dong-A Pharmaceutical
- National Institute of Nursing Research (NINR)
- Arizona State University
- Baylor University
- Dayton Children's Hospital
- University of Washington
- Medical College of Wisconsin
- Ahvaz Jundishapur University of Medical Sciences
- Wright State University
- Children's Medical Center of Dayton
- OpenBiome
Organization Involved with Other Experimental Indications (58)
- AB Biotics, SA
- BioGaia AB
- Danone Research
- Lesaffre International
- Verman Oy Ab
- Tereos
- SC Fiterman Pharma SRL
- Money, Mary E., M.D.
- Helse Fonna
- Ain Shams University
- Bay Area Retina Associates
- Children's Memorial Health Institute, Poland
- Iuppa Industriale Srl
- Macrohard Institute of Health
- Medical University of Lublin
- Nakatani Clinic
- Norwegian University of Science and Technology
- Ohio State University
- Royal Veterinary and Agricultural University, Denmark
- Shanghai University of Traditional Chinese Medicine
- Tohoku University
- University of Liverpool
- University of Southern Denmark
- Utrecht University
- University of Athens
- Wakayama Medical University
- Wingate Institute of Neurogastroenterology
- Statens Serum Institut
- University of Connecticut
- Clinical Emergency Hospital Sf. Spiridon Iasi
- +28 more